Share this article on:

Retinal Ganglion Cell Layer Analysis by Optical Coherence Tomography in Toxic and Nutritional Optic Neuropathy

Vieira, Luisa Margarida Cabral MD; Silva, Nuno Filipe Aguiar MD; Dias dos Santos, Arnaldo Miguel MD; Anjos, Rita Serrano dos MD; Pinto, Luis Alexandre Pereira Abegão MD, PhD; Vicente, André Rodrigues MD; Borges, Bárbara Isabel Correia Coelho Jardim MD; Ferreira, Joana Patrícia Tavares MD; Amado, Duarte Moreira MD; Cunha, João Paulo Pedrosa Branco da MD

doi: 10.1097/WNO.0000000000000229
Original Contribution

Objective: To analyze the retinal ganglion cell layer (RGL) by optical coherence tomography (OCT) in toxic and nutritional optic neuropathy and to correlate its thickness and volume with functional damage.

Methods: We conducted an observational cross-sectional study in healthy subjects and in patients with toxic optic neuropathy observed in the Neuro-Ophthalmology Department of Central Lisbon Hospital Center. Complete ophthalmologic examination, OCT (Heidelberg Spectralis), and automated static perimetry were performed. Thickness and macular volume of RGL layer and inner plexiform layer were measured after manual segmentation.

Results: The study included 16 eyes of 12 healthy subjects and 16 eyes of 8 patients with toxic and nutritional optic neuropathy. Age and gender did not differ between the 2 groups. Ethambutol was the cause of toxic optic neuropathy in 4 patients and nutritional factors (tobacco–alcohol) in 4 patients. A statistically significant decrease in thickness and volume of RGL, in all quadrants at 2 and 3 mm, was detected in individuals with optic neuropathy compared with controls (P < 0.01). A positive correlation between RGL thickness and mean deviation (MD) and between RGL volume and MD was detected (P < 0.05). There was a negative correlation between MD and time of disease (r = 0.846 P = 0.001) and a positive correlation between MD and visual acuity in logMAR (r = 0.739 P = 0.006). A majority of the structural parameters also correlated negatively with time of disease (P < 0.05).

Conclusions: Decreased RGL thickness and volume detected in this study support a mechanism of RGL toxicity. RGL analysis may contribute to the diagnosis and management of toxic and nutritional optic neuropathies.

Department of Ophthalmology (LMCV, NFAS, AMDdS, RSdA, LAPAP, ARV, BICCJB, JPTF, DMA, JPPBdC), Central Lisbon Hospital Center, Lisbon, Portugal; Faculty of Medicine (LAPAP), Institute of Pharmacology and Neurosciences, University of Lisbon, Lisbon, Portugal; and Faculty of Medical Sciences (JPPBdC), New University of Lisbon, Lisbon, Portugal.

Address correspondence to Luisa Margarida Cabral Vieira, MD, Rua Julieta Ferrão Edifício Gémeos, Bloco RS n°145, 1600-131 Lisboa, Portugal; E-mail: luisa5vieira@gmail.com

Presented as a poster at ARVO 2014, Association for Research in Vision and Ophthalmology.

The authors report no conflicts of interest.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the full text and PDF versions of this article on the journal's Web site (www.jneuro-ophthalmology.com).

Toxic and nutritional optic neuropathies (TNON) are characterized by bilateral, progressive, and painless vision loss (1). Ganglion cell toxicity has been proposed as a pathophysiologic mechanism in these optic neuropathies, although the precise mechanism remains poorly understood (2–5).

Typical patients with TNON develop central or cecocentral scotomas, and color vision and contrast sensitivity are impaired (1, 2, 4, 6). Early in the clinical course, the optic discs appear normal, and additional testing may be required to establish the correct diagnosis. In TNON, retinal nerve fiber layer (RNFL) thinning measured by optical coherence tomography (OCT) can be helpful in detecting disease before fundus changes appear. Thinning of the RNFL begins in the inferotemporal sector of papillomacular bundle and involves all quadrants in later stages (2, 7–9) but not before vision loss (10–12). Retinal ganglion cell layer (RGL) analysis by spectral domain OCT (SD-OCT) has been described in a variety of optic neuropathies, including glaucoma (13–18), optic neuritis (19, 20), nonarteritic ischemic optic neuropathy (21, 22), papilledema due to idiopathic intracranial hypertension (23), and Leber hereditary optic neuropathy (24).

The purpose of our study was to analyze RGL layer by SD-OCT in patients with TNON and correlate its thickness and volume with functional damage.

Back to Top | Article Outline

METHODS

Participant Selection

A prospective, observational cross-sectional study was performed on all patients with TNON in our Neuro-Ophthalmology Department from August 1, 2012 to July 31, 2013. Age- and sex-matched healthy controls were selected from the General Ophthalmology Department of the Central Lisbon Hospital Center. The diagnosis of TNON was established by a neuro-ophthalmologist after obtaining a careful history and excluding other causes of optic neuropathy including Leber hereditary optic neuropathy (negativity for the 3 major mitochondrial DNA mutations: 11778 G>A, 3460 G>A, and 14484T>C), autosomal dominant optic atrophy, inflammatory optic neuropathy, ischemic optic neuropathy, compressive optic neuropathy, and glaucoma. Patients were excluded with concomitant ocular or neurological disease and with refractive error ± 4 diopters. Based on self-reporting and analysis of medical records, we documented the time and onset of TNON.

Causative factors of the optic neuropathy were ethambutol (4 patients) and poor nutrition (alcohol–tobacco) (4 patients). Ethambutol was prescribed for pulmonary (3 patients) and renal (1 patient) tuberculosis. The regimen of 2 patients was 2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol followed by 4 months of isoniazid and ethambutol (2HRZE/6HE), 1 patient 3 times weekly and 1 daily. The regimen of the other 2 patients with isoniazid resistance was 6 months of rifampicin, pyrazinamide, and ethambutol (daily) (6RZE). Ethambutol dosage was 20 mg/kg on daily regimen and 35 mg/kg on 3 times weekly regimen. The first 2 patients were diagnosed during the continuation phase of treatment (fifth and seventh months) and the other 2 after the end of the treatment (1 and 2 months after completion). Patients with nutritional optic neuropathy had a long history of heavy tobacco use (30, 58, 44, and 75 pack-years) and alcohol consumption (252, 174, 286, 56 g daily for 13, 16, 14, and 30 years, respectively). One patient had low levels of vitamin B12 and folate, and the others had normal values. Two patients had high serum lactate levels.

Controls were healthy individuals based on the criteria of 20/20 visual acuity (VA) and no history of ocular, neurologic, or systemic disease.

Back to Top | Article Outline

Procedures

All participants underwent full ophthalmologic examination, SD-OCT (Heidelberg Engineering, Heidelberg, Germany), and automated static perimetry (ASP) using Octopus 900 (Haag-Streit, Switzerland). VA was calculated in logMAR. RGL segmentation was performed manually by transferring the points of the 2 boarding lines of the retina obtained automatically to RGL borders. Three to 9 points were needed to define the borders, depending on the boundary curvature. This segmentation, centered on the fovea, was performed in 25 horizontal scans with 6.1-mm length separated by 250 μm. The macular thickness (in micrometers) and volume (in cubic micrometers) of RGL (RGL and inner plexiform layer) were then obtained automatically, in a circular area centered on the fovea with 2 and 3 mm diameters, in superior (S), temporal (T), inferior (I), and nasal (N) quadrants (Fig. 1). ASP was acquired with Octopus strategy G2 and analyzed as mean deviation (MD in decibel). Two patients with TNON did not have reliable ASP results and were excluded from the analysis.

SD-OCT and ASP were evaluated offline by 1 masked observer.

Macular thickness and volume of RGL of the TNON group were compared with those of the control group. In the TNON group, macular thickness and volume of RGL, MD, VA, and time of disease were correlated.

Back to Top | Article Outline

Statistics

Statistical analysis was conducted using SPSS Statistics version 20.0. Mean and SD were calculated. Groups were compared using Mann–Whitney or χ2 tests. Spearman correlation was used to correlate TNON group variables. P values less than 0.05 were considered statistically significant.

Back to Top | Article Outline

Ethics Statement

The study followed the tenets of the Declaration of Helsinki, and written informed consent was obtained from all participants.

Back to Top | Article Outline

RESULTS

Clinical data of patients with TNON and controls are summarized in Table 1. Statistically significant differences were detected in VA and MD of the ASP.

A statistically significant decrease in the thickness and volume of RGL, in all quadrants at 2 and 3 mm, was detected in the optic neuropathy group compared with controls (P < 0.01). A greater decrease was detected in inferior thickness and volume at 2 mm and in nasal thickness and volume at 3 mm (see Supplemental Digital Content, Table E1, http://links.lww.com/WNO/A142).

A positive correlation (P < 0.05) between RGL thickness and MD and between RGL volume and MD was detected (see Supplemental Digital Content, Table E2, http://links.lww.com/WNO/A143, and Figs E1 and E2, http://links.lww.com/WNO/A137 and http://links.lww.com/WNO/A138).

A negative correlation between MD and time of disease (r = 0.846 P = 0.0001) and a positive correlation between MD and VA in logMAR (r = 0.739 P = 0.006) was also obtained (see Supplemental Digital Content, Table E2, http://links.lww.com/WNO/A143, and Fig E3, http://links.lww.com/WNO/A139).

The majority of the structural parameters also correlated negatively with time of disease (P < 0.05) (see Supplemental Digital Content, Table E3, http://links.lww.com/WNO/A144, Figs E4 and E5, http://links.lww.com/WNO/A140 and http://links.lww.com/WNO/A141).

Back to Top | Article Outline

DISCUSSION

Observer-dependent RGL analysis by manual segmentation has been validated by Wang et al (13). Using this method, our study detected decreased RGL thickness and volume in patients with TNON, supporting the premise that these optic neuropathies are primarily due to injury of the RGLs (2–4).

In the TNON group, MD decrease (MD values are positive with Octopus perimetry) correlated with VA increase and time of disease progression, which corroborates what has been reported in the literature (8, 12). With greater time of disease, there was a decrease in the thickness and volume of RGL, which, in conjunction to MD decrease and VA increase, raises questions about the functionality of the ganglion cells in the acute phase and at the end of toxic exposure. The greatest decrease in RGL thickness and volume of RGL layer occurred in the inferonasal quadrants, supporting early papillomacular bundle impairment in its inferotemporal sector (2, 8). This is consistent with histopathology studies (5,7).

A genetic predisposition of increased mitochondrial oxidative stress may be associated with TNON (25), and the pattern of RNFL and RGL loss seems similar to other mitochondrial optic neuropathies including Leber hereditary optic neuropathy (22, 26) and dominant optic atrophy (27, 28). Our study was limited by a small number of patients and the lack of complete genetic analysis of mitochondrial DNA, as we only tested for the major mutations of Leber hereditary optic neuropathy. Another limitation was the extrapolation of data collected from a cross-sectional study to the natural history of TNON. The course of the disease can only be evaluated properly in a long-term longitudinal follow-up study.

Back to Top | Article Outline

REFERENCES

1. Kerrison JB. Optic neuropathies caused by toxins and adverse drug reactions. Ophthalmol Clin North Am. 2004;17:481–488.
2. Altiparmak UE. Toxic optic neuropathies. Curr Opin Ophthalmol. 2013;24:534–539.
3. Heng JE, Vorwerk CK, Lessell E, Zurakowski D, Levin LA, Dreyer EB. Ethambutol is toxic to retinal ganglion cells via an excitotoxic pathway. Invest Ophthalmol Vis Sci. 1999;40:190–196.
4. Orssaud C, Roche O, Dufier JL. Nutritional optic neuropathies. J Neurol Sci. 2007;262:158–164.
5. Kinoshita J, Iwata N, Maejima T, Kimotsuki T, Yasuda M. Retinal function and morphology in monkeys with ethambutol-induced optic neuropathy. Invest Ophthalmol Vis Sci. 2012;53:7052–7062.
6. Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. Mayo Clin Proc. 2003;78:1409–1411.
7. Zoumalan CI, Agarwal M, Sadun AA. Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2005;243:410–416.
8. Chai SJ, Foroozan R. Decreased retinal fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol. 2007;91:895–897.
9. Mendoza-Santiesteban CE, Gonzalez-Garcia A, Hedges TR III, Hernandez-Silva Y, Columbie-Garbey Y, Fernández-Cherkasova L, Santiesteban-Freixas R, Casali SV. Optical coherence tomography for neuro-ophthalmologic diagnoses. Semin Ophthalmol. 2010;25:144–154.
10. Kee C, Hwang JM. Optical coherence tomography in a patient with tobacco-alcohol amblyopia. Eye (Lond). 2008;22:469–470.
11. Kim U, Hwang JM. Early stage ethambutol optic neuropathy: retinal nerve fiber layer and optical coherence tomography. Eur J Ophthalmol. 2009;19:466–469.
12. Kim YK, Hwang JM. Serial retinal nerve fiber layer changes in patients with toxic optic neuropathy associated with antituberculosis pharmacotherapy. J Ocul Pharmacol Ther. 2009;25:531–535.
13. Wang M, Hood DC, Cho JS, Ghadiali Q, De Moraes CG, Zhang X, Ritch R, Liebmann JM. Measurement of local retinal ganglion cell layer thickness in patients with glaucoma using frequency-domain optical coherence tomography. Arch Ophthalmol. 2009;127:875–881.
14. Raza AS, Cho J, de Moraes CG, Wang M, Zhang X, Kardon RH, Liebmann JM, Ritch R, Hood DC. Retinal ganglion cell layer thickness and local visual field sensitivity in glaucoma. Arch Ophthalmol. 2011;129:1529–1536.
15. Moreno PA, Konno B, Lima VC, Castro DP, Castro LC, Leite MT, Pacheco MA, Lee JM, Prata TS. Spectral-domain optical coherence tomography for early glaucoma assessment: analysis of macular ganglion cell complex versus peripapillary retinal nerve fiber layer. Can J Ophthalmol. 2011;46:543–547.
16. Firat PG, Doganay S, Demirel EE, Colak C. Comparison of ganglion cell and retinal nerve fiber layer thickness in primary open-angle glaucoma and normal tension glaucoma with spectral-domain OCT. Graefes Arch Clin Exp Ophthalmol. 2013;251:831–838.
17. Takayama K, Hangai M, Durbin M, Nakano N, Morooka S, Akagi T, Ikeda HO, Yoshimura N. A novel method to detect local ganglion cell loss in early glaucoma using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53:6904–6913.
18. Lee K, Kwon YH, Garvin MK, Niemeijer M, Sonka M, Abràmoff MD. Distribution of damage to the entire retinal ganglion cell pathway: quantified using spectral-domain optical coherence tomography analysis in patients with glaucoma. Arch Ophthalmol. 2012;130:1118–1126.
19. Saidha S, Syc SB, Durbin MK, Eckstein C, Oakley JD, Meyer SA, Conger A, Frohman TC, Newsome S, Ratchford JN, Frohman EM, Calabresi PA. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler. 2011;17:1449–1463.
20. Syc SB, Saidha S, Newsome SD, Ratchford JN, Levy M, Ford E, Crainiceanu CM, Durbin MK, Oakley JD, Meyer SA, Frohman EM, Calabresi PA. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 2012;135:521–533.
21. Aggarwal D, Tan O, Huang D, Sadun AA. Patterns of ganglion cell complex and nerve fiber layer loss in nonarteritic ischemic optic neuropathy by Fourier-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2012;53:4539–4545.
22. Gonul S, Koktekir BE, Bakbak B, Gedik S. Comparison on the ganglion cell complex and retinal nerve fibre layer measurements using Fourier domain optical coherence tomography to detect ganglion cell loss in non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol. 2013;97:1045–1050.
23. Marzoli SB, Ciasca P, Curone M, Cammarata G, Melzi L, Criscuoli A, Bussone G, D'Amico D. Quantitative analysis of optic nerve damage in idiopathic intracranial hypertension (IIH) at diagnosis. Neurol Sci. 2013;34(suppl 1):S143–S145.
24. Akiyama H, Kashima T, Li D, Shimoda Y, Mukai R, Kishi S. Retinal ganglion cell in Leber's hereditary optic neuropathy. Ophthalmology. 2013;120:1943–1944.
25. Korkiamäki P, Kervinen M, Karjalainen K, Majamaa K, Uusimaa J, Remes AM. Prevalence of the primary LHON mutations in Northern Finland associated with bilateral optic atrophy and tobacco-alcohol amblyopia. Acta Ophthalmol. 2013;91:630–634.
26. Barboni P, Carbonelli M, Savini G, Ramos Cdo V, Carta A, Berezovsky A, Salomao SR, Carelli V, Sadun AA. Natural history of Leber's hereditary optic neuropathy: longitudinal analysis of the retinal nerve fiber layer by optical coherence tomography. Ophthalmology. 2010;117:623–627.
27. Rönnbäck C, Milea D, Larsen M. Imaging of the macula indicates early completion of structural deficit in autosomal-dominant optic atrophy. Ophthalmology. 2013;120:2672–2677.
28. Barboni P, Savini G, Cascavilla ML, Caporali L, Milesi J, Borrelli E, La Morgia C, Valentino ML, Triolo G, Lembo A, Carta A, De Negri A, Sadun F, Rizzo G, Parisi V, Pierro L, Bianchi Marzoli S, Zeviani M, Sadun AA, Bandello F, Carelli V. Early macular retinal ganglion cell loss in dominant optic atrophy: genotype-phenotype correlation. Am J Ophthalmol. 2014;158:628–636.

Supplemental Digital Content

Back to Top | Article Outline
© 2015 by North American Neuro-Ophthalmology Society